title: Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report.
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA Department of Internal Medicine, Division of Hematology and Oncology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.
authors.forename: Al-Ola
authors.initials: AO
authors.lastname: Abdallah
authors.affiliation: Department of Internal Medicine, Division of Cardiology, University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA Department of Internal Medicine, Division of Cardiology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.
authors.forename: Srikanth
authors.initials: S
authors.lastname: Vallurupalli
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA Department of Internal Medicine, Division of Hematology and Oncology, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA AKunthur@uams.edu.
authors.forename: Anuradha
authors.initials: A
authors.lastname: Kunthur
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000074322:Antineoplastic Agents, Immunological / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006333:Heart Failure / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D000074322:Antineoplastic Agents, Immunological; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; D000068258:Bevacizumab; C516667:pazopanib